Nexalin Technology, Inc. (NXL)
NASDAQ: NXL · Real-Time Price · USD
3.900
+0.100 (2.63%)
Nov 21, 2024, 1:30 PM EST - Market open
Nexalin Technology Employees
Nexalin Technology had 6 employees as of December 31, 2023. The number of employees did not change compared to the previous year.
Employees
6
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$27,013
Profits / Employee
-$925,763
Market Cap
41.29M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 6 | 0 | - |
Dec 31, 2022 | 6 | -4 | -40.00% |
Dec 31, 2021 | 10 | 6 | 150.00% |
Dec 31, 2020 | 4 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Achilles Therapeutics | 215 |
Accelerate Diagnostics | 134 |
Omega Therapeutics | 94 |
iCAD, Inc. | 69 |
HCW Biologics | 45 |
LAVA Therapeutics | 37 |
VYNE Therapeutics | 10 |
CERo Therapeutics Holdings | 9 |
NXL News
- 20 days ago - Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on November 5th - GlobeNewsWire
- 20 days ago - Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements - GlobeNewsWire
- 20 days ago - LOBO EV and Nexalin Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Accesswire
- 24 days ago - Nexalin Technology Announces Landmark Study on Alzheimer's Disease and Deep Intracranial Frequency Stimulation Published in Journal of Alzheimer's Disease - GlobeNewsWire
- 27 days ago - Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Accesswire
- 4 weeks ago - Nexalin Technology Announces Planned Clinical Trial Utilizing Gen-3 Halo Headset in Partnership with UC San Diego & San Diego VA - GlobeNewsWire
- 5 weeks ago - New Study Shows Nexalin's Deep Intracranial Frequency Stimulation (DIFS) Significantly Improves Memory and Cognitive Function in Alzheimer's Patients - GlobeNewsWire
- 5 weeks ago - Nexalin Technology Appoints Carolyn Shelton as Senior Vice President of Clinical, Quality & Regulatory Affairs - GlobeNewsWire